USA flag logo/image

An Official Website of the United States Government

Liquid Array Protein Assay Platform

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
88740
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
AI077249
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ARRAYOMICS, INC.
ARRAYOMICS, INC. 9909 HIBERT ST, STE A SAN DIEGO, CA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: Liquid Array Protein Assay Platform
Agency: HHS
Contract: 1R43AI077249-01A1
Award Amount: $99,999.00
 

Abstract:

DESCRIPTION (provided by applicant): The aim of this project is to extend application of a novel liquid array' platform, based on Encoded Sortable Particle (ESP) technology, into the protein assay realm. ESPs are optically-encoded microfabricated particle s that can be manipulated using magnetic force. We will adapt our ESP-based liquid array system, which has already been successfully applied in the DNA space, to incorporate antibody-based protein detection assays in Phase I, and we will extend the scope o f protein assay coverage in Phase II. Phase I will consist of a 6-plex cytokine detection analysis, while Phase II is intended to accommodate assays of 1000-plex or more. In the protein space the ESP platform has significant advantages in cost, throughput, scalability, ease of use, and flexibility over existing bead-based liquid array and fixed array platforms. ESP technology has broad applicability and should be a valuable tool in the diagnosis, prognosis, and characterization of a variety of disease state s, including cancer, heart disease, arthritis and inflammatory diseases, kidney disease, liver disease, allergic responses, and infectious diseases (e.g. HIV). PUBLIC HEALTH RELEVANCE: ESP technology as applied to the protein assay space will provid e a broad platform for many different kinds of assays. The ESP platform is intrinsically versatile, and has the potential to be used in basic biomedical research, as well as high-throughput discovery and clinical diagnostics. The ability to control the par ticles magnetically (in a manner significantly different from magnetic beads) is a significant advantage. This technology should be useful in the diagnosis and prognosis of a variety of disease states, including cancer, heart disease, arthritis and inflamm atory diseases, kidney disease, and infectious diseases (e.g. HIV).

Principal Investigator:

David M. Rothwarf
8582452435
DROTHWARF@ARRAYOMICS.COM

Business Contact:


drothwarf@arrayomics.com
Small Business Information at Submission:

ARRAYOMICS, INC.
ARRAYOMICS, INC. 9909 HIBERT ST, STE A SAN DIEGO, CA 92131

EIN/Tax ID: 320005243
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No